Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N. Engl. J. Med.

Title: The New England journal of medicine

Publisher: New England Journal of Medicine (NEJM/MMS)

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): August 03 2017

Volume: 377

Issue: 5

Affiliations

[1 ] From Thomas Jefferson University, Philadelphia (C.V.P.); Boehringer Ingelheim, Ridgefield, CT (P.A.R., R.D., B.W.); Boehringer Ingelheim, Biberach (J.R., S.G., J.S.), Boehringer Ingelheim, Ingelheim am Rhein (J.K.), Klinikum Frankfurt Höchst, Frankfurt (T.S.), and Heidelberg University Hospital, Heidelberg (T.S.) - all in Germany; McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Feinberg School of Medicine, Northwestern University, Chicago (R.A.B.); Leiden University Medical Center, Leiden (M.V.H.), and Tergooi Hospital, Hilversum (P.W.K.) - both in the Netherlands; Boston University School of Medicine, Boston (E.M.H.); Tuen Mun Hospital, Hong Kong (C.-W.K.); Duke University School of Medicine, Durham, NC (J.H.L.); Middlemore Hospital (G.R.) and the University of Auckland (L.Y.) - both in Auckland, New Zealand; Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence (F.W.S.); and KU Leuven, Center for Molecular and Vascular Biology, Leuven, Belgium (P.V.).

Article

DOI: 10.1056/NEJMoa1707278

PubMed ID: 28693366

SO-VID: bb0dab06-ef43-4316-aaf8-30730a709acd

History

Data availability:

Comments

Comment on this article

scite_

Cited by 221

See all cited by